Company Encyclopedia
View More
name
Abbvie
ABBV.US
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.
1.946 T
ABBV.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking51/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE138.53%A
    • Profit Margin4.00%C
    • Gross Margin71.75%A
  • Growth ScoreC
    • Revenue YoY7.40%B
    • Net Profit YoY-53.79%D
    • Total Assets YoY-6.64%D
    • Net Assets YoY-142.81%E
  • Cash ScoreB
    • Cash Flow Margin2540.20%A
    • OCF YoY7.40%B
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreE
    • Gearing Ratio101.94%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer

    An AbbVie-sponsored symposium at ESMO Asia 2025 addressed the critical need for new strategies to define and treat platinum resistance in advanced ovarian cancer. Experts highlighted that platinum-resistant advanced ovarian cancer has a poor prognosis and current treatment options are limited and often accompanied by significant side effects, affecting patients' quality of life. The discussion emphasized exploring novel approaches, including Antibody Drug Conjugates (ADCs), to improve efficacy, tolerability, and patient outcomes in this challenging disease.

    PR Newswire·
    US
    ABBV
    -0.66%
    PR Newswire·
    US
    ABBV
    -0.66%

    Amgen Inc. Stock Underperforms Thursday When Compared To Competitors

    Amgen Inc. shares fell 1.52% to $340.16 on Thursday, underperforming compared to competitors. The S&P 500 Index rose 0.11%, while the Dow Jones Industrial Average fell 0.07%. Amgen's stock ended a two-day winning streak and closed 1.80% below its 52-week high. Competitors' performances varied: Johnson & Johnson fell 1.39%, Pfizer rose 0.51%, and AbbVie fell 0.66%. Trading volume was 3.4 million, above the 50-day average of 2.5 million.

    Dow Jones·
    US
    JNJ
    -1.39%
    US
    AMGN
    -1.52%
    US
    ABBV
    -0.66%
    Dow Jones·
    US
    JNJ
    -1.39%
    US
    AMGN
    -1.52%
    US
    ABBV
    -0.66%

    First Trust Advisors LP Trims Stake in AbbVie Inc. $ABBV

    First Trust Advisors LP reduced its stake in AbbVie Inc. by 43.5% in Q2, owning 1,502,221 shares worth $278.84 million. AbbVie reported Q3 earnings of $1.86 per share, beating estimates, with revenue up 9.1% year-over-year. The company increased its quarterly dividend to $1.73 per share. Analysts have mixed ratings, with a consensus target price of $241.85.

    Market Beat·
    US
    ABBV
    -0.66%
    Market Beat·
    US
    ABBV
    -0.66%

    AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

    AbbVie Inc.'s stock rose 2.62% to $230.24, outperforming competitors like Johnson & Johnson and Pfizer on a strong trading day. The S&P 500 and Dow Jones also saw gains. AbbVie's stock remains 5.95% below its 52-week high. Trading volume was below average.

    Dow Jones·
    US
    ABBV
    -0.66%
    Dow Jones·
    US
    ABBV
    -0.66%

    TherapeuticsMD Inc. Stock Underperforms Tuesday When Compared To Competitors

    TherapeuticsMD Inc. (TXMD) stock fell 3.95% to $1.46 on Tuesday, underperforming compared to competitors like AbbVie Inc. (ABBV), which fell 0.33%. The NASDAQ Composite Index rose 0.59%, and the Dow Jones Industrial Average rose 0.39%. TXMD's trading volume was significantly below its 50-day average. The stock is 40.16% below its 52-week high.

    Dow Jones·
    US
    ABBV
    -0.66%
    Dow Jones·
    US
    ABBV
    -0.66%
    Posts
    View More

    Some names that caught my eye and on homework list. They might not make it to watch list. ABBV ACHR JOBY ADBE ENVX NOC LMT SMR TEM TOST ASTS DLR FAST IGV XLE

    Source: Sunrise Trader

    $Tesla(TSLA.US)Q1 earnings picks up next week with 1,400+ companies set to report. Watch for: $Alphabet(GOOGL.US), $AT & T(T.US)esla(TSLA.US), $Procter & Gamble(PG.US), $Abbvie(ABBV.US), $AT & T(T.US).............................................

    • 0
    © 2025 Longbridge｜Disclaimer